TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30878794

Group type: EXPERIMENTAL
Intervention: Full vouchers and conditional cash transfers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neither vouchers nor cash transfers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Voucher without cash transfer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unconditional cash transfer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Text messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Government policy to eliminate user fees
Number of subjects: 0
Study: 29742258

Group type: EXPERIMENTAL
Intervention: Power Bleaching 10% containing potassium oxalate
Number of subjects: 25

Group type: COMPARATOR
Intervention: Opalescence 10%
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Visual analogue scale and CoVAS
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TSA II
Number of subjects: 25
Study: 26341327

Group type: EXPERIMENTAL
Intervention: Caregiver strain assessed with the Caregiver Strain Index (CSI)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Patient functional status
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Patient emotional functioning
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Caregiver passive coping style
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Caregiver symptoms of anxiety
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Caregiver perceived quality of care
Number of subjects: 126
Study: 24594361

Group type: EXPERIMENTAL
Intervention: Adult passenger providing driving tips
Number of subjects: 3

Group type: COMPARATOR
Intervention: Silent adult passenger
Number of subjects: 3

Group type: COMPARATOR
Intervention: Driving alone
Number of subjects: 3
Study: 22098541

Group type: EXPERIMENTAL
Intervention: RD-CODOX-M/IVAC regimen with rituximab and liposome-encapsulated cytarabine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RD-CODOX-M/IVAC regimen
Number of subjects: 30
Study: 20924215

Group type: EXPERIMENTAL
Intervention: Clevudine 30 mg daily
Number of subjects: 92

Group type: COMPARATOR
Intervention: Lamivudine 100 mg daily
Number of subjects: 92
Study: 17650294

Group type: EXPERIMENTAL
Intervention: Hepimmune vaccine (four injections in 2 weeks intervals)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard HBV vaccine (HBVAXPRO)
Number of subjects: 15
Study: 16084873

Group type: EXPERIMENTAL
Intervention: Preimplantation genetic diagnosis (PGD)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Comparison group of women undergoing PGD for advanced maternal age (> or =35 years)
Number of subjects: 301
Study: 12182370

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand gel with multifaceted quality improvement (QI) interventions
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard handwashing and glove use
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand gel
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand gel with QI support
Number of subjects: 62
Study: 9476749

Group type: EXPERIMENTAL
Intervention: Late sleep deprivation (LSD) twice weekly during week 1 and 2 followed by LSD once weekly during week 3 and 4
Number of subjects: 44

Group type: COMPARATOR
Intervention: Late sleep deprivation (LSD) once weekly
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Late sleep deprivation (LSD) twice weekly followed by once weekly
Number of subjects: 44
Study: 7884117

Group type: EXPERIMENTAL
Intervention: Amrinone (5 and 10 micrograms/kg/min)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dobutamine (5 and 10 micrograms/kg/min)
Number of subjects: 14
Study: 2146040

Group type: EXPERIMENTAL
Intervention: Patients with left ventricular dysfunction (no overt heart failure)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Patients with overt heart failure
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Patients on diuretic therapy
Number of subjects: 288

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 288
Study: 219471

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (diuretic therapy)
Number of subjects: 23
Study: 31907833

Group type: EXPERIMENTAL
Intervention: Sublingual trinitroglycerin (TNG)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine (AD)
Number of subjects: 132

Group type: COMPARATOR
Intervention: HUTT-negative patients
Number of subjects: 132
Study: 31915072

Group type: EXPERIMENTAL
Intervention: High-dose intravenous vitamin C (50 mg/kg every 6 h for 96 h)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: High-dose intravenous vitamin C
Number of subjects: 800
Study: 30731195

Group type: EXPERIMENTAL
Intervention: Nucleot(s)ide analogue therapy
Number of subjects: 0
Study: 27681658

Group type: EXPERIMENTAL
Intervention: Provider-Supported arm
Number of subjects: 1229

Group type: COMPARATOR
Intervention: Patient Self-Directed Care arm
Number of subjects: 1229
Study: 26460293

Group type: EXPERIMENTAL
Intervention: Budesonide 160 μg (80 μg × 2 inhalations) twice daily via pMDI
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 23324079

Group type: EXPERIMENTAL
Intervention: Sorafenib in combination with TACE
Number of subjects: 304

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 304
Study: 20666876

Group type: EXPERIMENTAL
Intervention: CO(2) laser therapy
Number of subjects: 191

Group type: COMPARATOR
Intervention: Cryotherapy + intralesional meglumine antimoniate
Number of subjects: 191
Study: 19803786

Group type: EXPERIMENTAL
Intervention: Citicoline (1000 mg twice a day)
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Placebo (twice a day)
Number of subjects: 1292
Study: 17076839

Group type: EXPERIMENTAL
Intervention: Leukoreduced blood transfusion
Number of subjects: 67

Group type: COMPARATOR
Intervention: Nonleukoreduced blood transfusion
Number of subjects: 67
Study: 15187173

Group type: EXPERIMENTAL
Intervention: Observed family relationship quality
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Observed family problem solving
Number of subjects: 96
Study: 11689496

Group type: EXPERIMENTAL
Intervention: Screening group (attended two screening sessions)
Number of subjects: 7229

Group type: COMPARATOR
Intervention: Control group (received conventional medical care)
Number of subjects: 7229

Group type: EXPERIMENTAL
Intervention: Screening group
Number of subjects: 7229

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7229
Study: 9177956

Group type: EXPERIMENTAL
Intervention: Fluoxetine plus total sleep deprivation (TSD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fluoxetine alone
Number of subjects: 10
Study: 8131470

Group type: EXPERIMENTAL
Intervention: Continuous irrigation suction catheter (Irri-cath)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional intermittent suction catheter
Number of subjects: 20
Study: 3304827

Group type: EXPERIMENTAL
Intervention: Copper-T-200 (CuT)
Number of subjects: 19821

Group type: EXPERIMENTAL
Intervention: Multiload-250 (ML)
Number of subjects: 19821

Group type: EXPERIMENTAL
Intervention: Nova-T (NoT)
Number of subjects: 19821

Group type: COMPARATOR
Intervention: All IUDs
Number of subjects: 19821
Study: 30243062

Group type: EXPERIMENTAL
Intervention: Target group (mean arterial pressure (MAP) ≥ 90% of preoperative values)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No-Target group (more liberal intraoperative blood pressure management)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 101
Study: 28967054

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA) coated SL-PLUS stem
Number of subjects: 51

Group type: COMPARATOR
Intervention: Uncoated SL-PLUS stem
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups (HA-coated and uncoated)
Number of subjects: 51
Study: 26174080

Group type: EXPERIMENTAL
Intervention: EMD/synthetic bone graft (SBG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: EMD
Number of subjects: 30
Study: 25096315

Group type: EXPERIMENTAL
Intervention: Cognitive behavior group therapy for back pain (CBT-BP), six sessions.
Number of subjects: 103

Group type: COMPARATOR
Intervention: Unspecific occupational therapy sessions (control group).
Number of subjects: 103
Study: 23010155

Group type: EXPERIMENTAL
Intervention: Personalized primary tumor xenograft model
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 20
Study: 20814330

Group type: EXPERIMENTAL
Intervention: Paliperidone ER (6 mg/d, flexible dosing 3-12 mg/d)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 18060972

Group type: EXPERIMENTAL
Intervention: Stress urinary incontinence surgery
Number of subjects: 655
Study: 15953743

Group type: EXPERIMENTAL
Intervention: Isotonic MgSO4 (2.5 ml, 6.3%) + salbutamol (2.5 ml)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline (2.5 ml) + salbutamol (2.5 ml)
Number of subjects: 26
Study: 11807630

Group type: EXPERIMENTAL
Intervention: Menatetrenone (45 mg oral administration)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no menatetrenone)
Number of subjects: 18
Study: 10578913

Group type: EXPERIMENTAL
Intervention: German language RCTs
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hand search of nursing journals
Number of subjects: 15
Study: 7751498

Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 21

Group type: COMPARATOR
Intervention: Tissue-type plasminogen activator
Number of subjects: 21
Study: 2189719

Group type: EXPERIMENTAL
Intervention: Citric acid aerosol (with or without flavor additives)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citric acid inhalers used throughout 8 hours of cigarette deprivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cigarette
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 378016

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 72
Study: 31336492

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 20

Group type: COMPARATOR
Intervention: MICT
Number of subjects: 20
Study: 28152219

Group type: EXPERIMENTAL
Intervention: Prophylactic PEG tube
Number of subjects: 134

Group type: COMPARATOR
Intervention: Common clinical nutritional support
Number of subjects: 134
Study: 25663605

Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral hernia repair (LVHR) with defect closure (transfascial sutures)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Laparoscopic ventral hernia repair (LVHR) without defect closure
Number of subjects: 143
Study: 23507787

Group type: EXPERIMENTAL
Intervention: Clinical management + NT-proBNP monitoring
Number of subjects: 407

Group type: COMPARATOR
Intervention: Clinical management
Number of subjects: 407
Study: 21037266

Group type: EXPERIMENTAL
Intervention: Increased workload during simulated critical incidents (sessions 2 and 3)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No critical incident simulated (session 1)
Number of subjects: 15
Study: 19010347

Group type: EXPERIMENTAL
Intervention: Walking intervention group (n=24; 5 males) gradually increasing walking by 3000 steps/day on 5 days of the week.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (n=24; 6 males, no change in walking).
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups measured for glucose, insulin, hsCRP, IL-6, sIL-6R, TNF-alpha, sTNFR1 and sTNFRII.
Number of subjects: 48
Study: 17869634

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 18023

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 18023

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 18023
Study: 15149258

Group type: EXPERIMENTAL
Intervention: Hearing instructions previewing movements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Instructions following the movements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants' own movement mimicry
Number of subjects: 0
Study: 16206668

Group type: EXPERIMENTAL
Intervention: Psychotherapy and Fluoxetine (20mg once a day for 12 weeks)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Regular cardiac medicine therapy
Number of subjects: 76
Study: 9486551

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Primary open-angle glaucoma (POAG) patients
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Normal-tension glaucoma (NTG) patients
Number of subjects: 178
Study: 8057649

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy with vindesine (3 mg/m2 weekly x 5, then every 2 weeks x 8) and cisplatin (120 mg/m2 on days 1, 29, 71, 113) plus thoracic irradiation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation
Number of subjects: 72
Study: 2522134

Group type: EXPERIMENTAL
Intervention: 2.5 mg of amlodipine
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 5 mg of amlodipine
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 10 mg of amlodipine
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 30891721

Group type: EXPERIMENTAL
Intervention: moodgym + treatment as usual (TAU)
Number of subjects: 647

Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 647
Study: 28708316

Group type: EXPERIMENTAL
Intervention: Plant sterols supplementation (2.0 g free plant sterols equivalent of palmityl esters daily for 4 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18
Study: 25044345

Group type: EXPERIMENTAL
Intervention: Resorbable collagen‐based tetracycline fibers (Periodontal Plus AB fibers) adjunct to scaling and root planing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Scaling and root planing (monotherapy)
Number of subjects: 40
Study: 23311889

Group type: EXPERIMENTAL
Intervention: Patient education plus supervised exercise (3 months, 12 sessions of individualized neuromuscular training, 12 sessions of intensive resistance training, and 3 sessions of patient education)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient education alone (3 sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient education plus supervised exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient education alone
Number of subjects: 0
Study: 21591986

Group type: EXPERIMENTAL
Intervention: Experimental cheese (from milk produced by cows fed a grass and maize silage based diet with 5% of linseed oil added)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control cheese (from normal cows' milk)
Number of subjects: 30
Study: 18307489

Group type: EXPERIMENTAL
Intervention: Exercise support program (1 hour per week at the hospital and two sessions at home for 3 months)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 80
Study: 16582045

Group type: EXPERIMENTAL
Intervention: Venlafaxine (titrated from 37.5 to 225 mg per day)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Fluoxetine (titrated from 20 to 60 mg per day)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 300
Study: 12619027

Group type: EXPERIMENTAL
Intervention: Molecular adsorbents recirculating system (MARS) treatment for 6 hours
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (mechanically cooled)
Number of subjects: 13
Study: 10732888

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 401

Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 401
Study: 8626096

Group type: EXPERIMENTAL
Intervention: LEEP (149 patients)
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Excisional laser (145 patients)
Number of subjects: 639

Group type: COMPARATOR
Intervention: LEEP
Number of subjects: 639

Group type: COMPARATOR
Intervention: Excisional laser
Number of subjects: 639

Group type: COMPARATOR
Intervention: Both arms (LEEP and excisional laser)
Number of subjects: 639

Group type: COMPARATOR
Intervention: Classical management
Number of subjects: 639
Study: 1596064

Group type: EXPERIMENTAL
Intervention: 100 mg of lidocaine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6379506

Group type: EXPERIMENTAL
Intervention: Intramuscular gangliosides (40 mg/d) for 6 months
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31003921

Group type: EXPERIMENTAL
Intervention: Low serum uromodulin (SUMOD)
Number of subjects: 0
Study: 29522203

Group type: EXPERIMENTAL
Intervention: Pre-EBV < 2300 copies/ml
Number of subjects: 208

Group type: COMPARATOR
Intervention: Pre-EBV ≥ 2300 copies/ml
Number of subjects: 208
Study: 26308287

Group type: EXPERIMENTAL
Intervention: In-home test kit and educational material
Number of subjects: 60

Group type: COMPARATOR
Intervention: Educational material only (Control)
Number of subjects: 60
Study: 25274230

Group type: EXPERIMENTAL
Intervention: >80 °C hot water
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Antiseptic wipes
Number of subjects: 60

Group type: COMPARATOR
Intervention: No disinfection (control group)
Number of subjects: 60
Study: 22574590

Group type: EXPERIMENTAL
Intervention: Wenshen Huatan Recipe (WHR)
Number of subjects: 90
Study: 20581337

Group type: EXPERIMENTAL
Intervention: Reinforced feedback in a virtual environment (RFVE)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 47
Study: 17909323

Group type: EXPERIMENTAL
Intervention: Self-learning modules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional lecture/discussion
Number of subjects: 0
Study: 15867241

Group type: EXPERIMENTAL
Intervention: Temozolomide (200 mg/m2 oral administration)
Number of subjects: 12
Study: 12115158

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg twice daily plus nimesulide
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo plus nimesulide
Number of subjects: 36
Study: 11110328

Group type: EXPERIMENTAL
Intervention: Routine sponge bath on Day 1, followed by no bathing for 4 days
Number of subjects: 45
Study: 8638531

Group type: EXPERIMENTAL
Intervention: Filgrastim (5 micrograms/kg s.c. days 4‐17, 24‐37) during MMM treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (MMM alone)
Number of subjects: 31
Study: 1448662

Group type: EXPERIMENTAL
Intervention: IA BCNU
Number of subjects: 315

Group type: COMPARATOR
Intervention: IV BCNU
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: IA cisplatin
Number of subjects: 315

Group type: COMPARATOR
Intervention: IV PCNU
Number of subjects: 315
Study: 6580926

Group type: EXPERIMENTAL
Intervention: Amsacrine-containing regimen
Number of subjects: 16

Group type: COMPARATOR
Intervention: Daunorubicin-containing regimen
Number of subjects: 16
Study: 30777574

Group type: EXPERIMENTAL
Intervention: Structured diabetes education
Number of subjects: 210

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 210
Study: 29178434

Group type: EXPERIMENTAL
Intervention: PF-06273340 400 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PF-06273340 50 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27495085

Group type: EXPERIMENTAL
Intervention: PEG‐INF‐α2a plus ADV (started at week 0)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PEG‐INF‐α2a plus ADV (started at week 12)
Number of subjects: 120

Group type: COMPARATOR
Intervention: PEG‐INF‐α2a monotherapy (group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PEG‐INF‐α2a plus ADV (started at week 24)
Number of subjects: 120
Study: 24556343

Group type: EXPERIMENTAL
Intervention: 4g/day purified long chain omega-3 fatty acids (Omacor)
Number of subjects: 103

Group type: COMPARATOR
Intervention: 4g/day olive oil (placebo)
Number of subjects: 103
Study: 23103485

Group type: EXPERIMENTAL
Intervention: Collagen dressing (Suprasorb C) covered with foam dressing (Suprasorb P)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Foam dressing (Suprasorb P) as primary dressing
Number of subjects: 10
Study: 20651749

Group type: EXPERIMENTAL
Intervention: Travoprost/timolol fixed combination (TTFC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 40
Study: 18341655

Group type: EXPERIMENTAL
Intervention: Pentaherbs formulation (PHF)
Number of subjects: 28
Study: 15978303

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (2 sprays per nostril twice daily)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Cetirizine (10-mg tablets once daily)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 307

Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 307
Study: 12707645

Group type: EXPERIMENTAL
Intervention: 4% cocaine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.05% oxymetazoline
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study: 10334231

Group type: COMPARATOR
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.1-50 micromol)
Number of subjects: 0
Study: 8945077

Group type: EXPERIMENTAL
Intervention: 600 mg of oral propafenone administered two hours before pacing (group B)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No treatment (group A)
Number of subjects: 12
Study: 30288682

Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil 6 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil 20 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Baloxavir marboxil (various doses: 6, 20, 40, 60, 80 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil (various doses)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil
Number of subjects: 31
Study: 27495190

Group type: EXPERIMENTAL
Intervention: Baum cuff (BC)
Number of subjects: 102
Study: 24854817

Group type: EXPERIMENTAL
Intervention: Self-reported unhealthy weight loss behaviors (e.g., fasting, purging)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Symptoms of depression (measured by the Center for Epidemiologic Studies Depression short form)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Interactions between gender and depression
Number of subjects: 404